Anne Troldborg
Overview
Explore the profile of Anne Troldborg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larsen M, Norgaard L, Linge P, Larsen J, Langkilde H, Hauge E, et al.
Semin Arthritis Rheum
. 2025 Mar;
72:152707.
PMID: 40086157
Patients with systemic lupus erythematosus (SLE) face an approximately 30 % risk of thrombosis post-diagnosis. However, there remains significant knowledge gaps regarding causative mechanisms, and there is a lack of...
2.
Geday S, Prior A, Pedersen H, de Thurah A, Naeser E, Troldborg A
Ann Rheum Dis
. 2025 Feb;
PMID: 40000262
Objectives: This study aimed to analyse healthcare utilisation patterns in the 5 years preceding a diagnosis of systemic lupus erythematosus (SLE) in Denmark compared to matched healthy individuals. Understanding these...
3.
Mistegaard C, Troldborg A, Torgutalp M, Loft A, Thiel S, Muche B, et al.
Rheumatol Adv Pract
. 2025 Feb;
9(1):rkaf007.
PMID: 39959130
Objectives: To investigate lectin pathway proteins (LPPs) and complement activation marker C3dg as biomarkers for disease activity and treatment response in a multicentre, randomized controlled trial of axial spondyloarthritis (axSpA)...
4.
Larsen M, Voss A, Nielsen C, Hauge E, Faurschou M, Troldborg A
Ugeskr Laeger
. 2024 Nov;
186(47).
PMID: 39575908
Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies...
5.
Ammitzboll C, Thomsen M, Erikstrup C, Troldborg A
Rheum Dis Clin North Am
. 2024 Nov;
51(1):45-59.
PMID: 39550106
This article provides a comprehensive review of the impact of B-cell-directed therapy on severe acute respiratory syndrome coronavirus 2 vaccine immunity, focusing on its implications in autoimmune inflammatory rheumatic diseases...
6.
Orum M, Lund Laursen A, Troldborg A
BMJ Case Rep
. 2024 Sep;
17(9.
PMID: 39304216
This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to...
7.
Larsen M, Skouboe M, Mogensen T, Lund Laursen A, Deleuran B, Troldborg A, et al.
Am J Case Rep
. 2024 Sep;
25:e944505.
PMID: 39245905
BACKGROUND Anifrolumab, a monoclonal antibody targeting the type 1 interferon (IFN-I) signaling pathway, holds promise as a therapeutic intervention for systemic lupus erythematosus (SLE). However, its use is associated with...
8.
Rasch M, Szabados F, Jensen J, Nielsen K, Hauge E, Troldborg A
RMD Open
. 2024 Jul;
8(2).
PMID: 38967099
Background: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) is an autoinflammatory condition with overlapping features of rheumatology and haematology caused by somatic mutations in the UBA1 gene. Patients present with...
9.
Ammitzboll C, Thomsen M, Bartels L, Hansen C, Hermansen M, Hanel M, et al.
ACR Open Rheumatol
. 2024 Jun;
6(8):519-528.
PMID: 38923834
Objective: Rituximab (RTX)-treated patients exhibit suboptimal responses to COVID-19 vaccines. However, existing research primarily involves patients already receiving RTX when vaccines were introduced, failing to account for the current landscape...
10.
Troldborg A, Remkus L, Eek D, Deleuran B
Lupus
. 2024 Jun;
33(9):962-973.
PMID: 38901042
Anifrolumab is a new therapeutic approach for individuals with systemic lupus erythematosus (SLE) directed at blocking the type 1 interferon pathway. Despite the expanding body of literature on Anifrolumab, an...